eFFECTOR Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EFTR research report →
Companyeffector.com
eFFECTOR Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer.
- CEO
- Davide Ruggero
- IPO
- 2021
- Employees
- 14
- HQ
- Solana Beach, CA, US
Price Chart
Valuation
- Market Cap
- $2.35K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.17
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 3771.56%
- ROIC
- -221.30%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-35,811,000 · -177.02%
- EPS
- $-16.37 · -108.54%
- Op Income
- $-33,844,000
- FCF YoY
- -13.63%
Performance & Tape
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 2.42
- Avg Volume
- 788
Get TickerSpark's AI analysis on EFTR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 13, 24 | Loewy Caroline M | other | 800 |
| Jun 13, 24 | Klencke Barbara | other | 800 |
| Jun 13, 24 | Ehrlich Christopher B | other | 800 |
| Jun 13, 24 | Harrington-Smith Kristen | other | 800 |
| Jun 13, 24 | Gallagher Brian M. Jr. | other | 800 |
| Jun 13, 24 | Bhatt Elizabeth | other | 800 |
| May 15, 24 | Byrnes Michael | other | 1,387 |
| May 15, 24 | WORLAND STEPHEN T | other | 1,806 |
| Feb 19, 24 | Loewy Caroline M | other | 2,000 |
| Feb 19, 24 | Bhatt Elizabeth | other | 2,000 |
Our EFTR Coverage
We haven't published any research on EFTR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate EFTR Report →